← Back to overview

MRNA Moderna, Inc.

Biotechnology · $54.07 -5.17%
EN PL
Price Alert:

Compare

Shows % change over the period so different-priced stocks can be compared fairly.

Technical Indicators

RSI (14)
51.1
Relative Strength Index (RSI): measures how fast and how much the price has moved recently, on a 0-100 scale. Above 70 is often called "overbought" (may be due for a pause or pullback); below 30 is "oversold" (may be due for a bounce). It is not a guarantee either way.
SMA 20 / 50 / 200
54.89 / 41.91 / 82.07
Moving Averages (SMA): the average closing price over the last N days, smoothing out day-to-day noise. When price trades above its moving averages, and shorter averages are above longer ones, it is generally read as a healthier trend.
MACD / Signal
5.33 / 5.67
MACD: compares two moving averages (12-day and 26-day) to gauge momentum. When the MACD line crosses above its signal line, momentum is turning up; crossing below suggests momentum turning down.

Fundamentals

P/E
Price-to-Earnings ratio: how many dollars investors pay for $1 of the company's annual profit. Higher usually means the market expects faster growth (or the stock is expensive); lower can mean it's cheap — or that growth is expected to slow.
Market Cap
21.45B
Market Capitalization: the total value of all the company's shares — share price × number of shares. A rough measure of company size.
Div Yield
Dividend Yield: the annual cash dividend paid to shareholders, as a percentage of the current share price.
52-Week Range
22.28 – 85.60
52-Week Range: the lowest and highest price the stock has traded at over the last year. Where the price sits in this range hints at recent strength or weakness.

Trend Analysis

Moderna, Inc. is trading at $54.07, -5.17% versus the previous close. The price sits roughly in the middle of its 52-week range.
RSI is in a neutral range — no strong overbought/oversold signal.
The 50-day average is below the 200-day average ("death cross" territory) — a commonly watched bearish signal.
MACD is below its signal line — momentum currently leans negative.
Combine this reading with the fundamentals below before forming a view — no single indicator is a guarantee of what happens next.

Latest News

FDA Showdown Week: CAPR, NRXP, REPL And MRNA Face Make-Or-Break Regulatory Decisions
Stocktwits · 2026-07-25 00:30
Will Moderna (MRNA) Report Negative Earnings Next Week? What You Should Know
Zacks · 2026-07-24 14:00
Dassault Systemes SE (DASTF) (H1 2026) Earnings Call Highlights: Strong Subscription Growth and ...
GuruFocus.com · 2026-07-23 15:01
Is Arrowhead Pharmaceuticals Stock A Smart Buy After Its Transition To A Commercial Company?
Trefis · 2026-07-23 15:00
Earnings Preview: What To Expect From Moderna’s Report
Barchart · 2026-07-23 11:44
Cheiron Raises $8M Seed Led by Menlo Ventures to Build the Operating System for Drug Programs
GlobeNewswire · 2026-07-22 16:00
Fishbone Advisors Survey: Institutional Investors See Healthcare's AI Story as Overblown
Business Wire · 2026-07-22 10:00
Is Moderna (MRNA) Fully Valued As Board Changes And Earnings Near?
Simply Wall St. · 2026-07-22 04:29
Educational information only. Nothing here is investment advice — always do your own research and consider talking to a licensed financial advisor before buying or selling.
Data: Yahoo Finance, refreshed periodically and cached locally.